Cytokinetics (CYTK) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to $49.8 million.
- Cytokinetics' Accumulated Expenses rose 5119.86% to $49.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $49.8 million, marking a year-over-year increase of 5119.86%. This contributed to the annual value of $42.6 million for FY2023, which is 329.96% down from last year.
- Latest data reveals that Cytokinetics reported Accumulated Expenses of $49.8 million as of Q3 2024, which was up 5119.86% from $39.8 million recorded in Q2 2024.
- Cytokinetics' 5-year Accumulated Expenses high stood at $49.8 million for Q3 2024, and its period low was $9.7 million during Q1 2020.
- Moreover, its 5-year median value for Accumulated Expenses was $33.0 million (2023), whereas its average is $30.7 million.
- As far as peak fluctuations go, Cytokinetics' Accumulated Expenses tumbled by 2523.95% in 2020, and later soared by 11932.9% in 2021.
- Over the past 5 years, Cytokinetics' Accumulated Expenses (Quarter) stood at $19.3 million in 2020, then surged by 77.94% to $34.4 million in 2021, then rose by 28.3% to $44.1 million in 2022, then dropped by 3.3% to $42.6 million in 2023, then rose by 16.85% to $49.8 million in 2024.
- Its Accumulated Expenses was $49.8 million in Q3 2024, compared to $39.8 million in Q2 2024 and $40.1 million in Q1 2024.